41049-53-0

Usage

Uses

Used in Pharmaceutical Research and Development:
1-Phenyl-cyclopropylamine is used as a building block in organic synthesis for the development of new medications, particularly in the pharmaceutical industry. Its unique structure and reactivity make it a valuable component in the creation of innovative drugs.
Used in Psychiatric Disorders Treatment:
1-Phenyl-cyclopropylamine is used as a potential therapeutic agent for treating depression and other psychiatric disorders. Its ability to act as a potent serotonin releaser and reuptake inhibitor has led to studies exploring its efficacy in managing these conditions.
Used in Chemical Production:
1-Phenyl-cyclopropylamine is used in the production of various chemicals, such as dyes and pharmaceuticals, due to its versatile reactivity and potential therapeutic effects. Its presence in these products contributes to their unique properties and applications.
Used in Controlled Laboratory Settings:
1-Phenyl-cyclopropylamine is used with caution in controlled laboratory settings due to its toxic nature. Proper handling and safety measures are essential to prevent adverse effects and ensure the safe use of PCA in research and development.

InChI:InChI=1/C9H11N/c10-9(6-7-9)8-4-2-1-3-5-8/h1-5H,6-7,10H2

Upstream product

• 223513-67-5 N-(1-phenyl-cyclopropyl)-acetamide 
• 925-90-6 ethylmagnesium bromide 
• 100-47-0 benzonitrile 
• 140-29-4 phenylacetonitrile 
• 736055-06-4 (1-phenyl-cyclopropyl)-carbamic acid ethyl ester 
• 1007-71-2 1-(1-phenyl-cyclopropyl)-ethanone 
• 935-44-4 1-cyano-1-phenylcyclopropane 
• 557-20-0 diethylzinc 
• 6120-95-2 1-phenyl-1-cyclopropane carboxylic acid 

Downstream Products

• 137596-54-4 1-Phenyl-3-(1-phenyl-cyclopropylamino)-propan-1-one 
• 692737-74-9 N-(1-phenyl-1-cyclopropyl)-D-alanine ethyl ester 
• 1217348-10-1 4-((1H-1,2,4-triazol-1-yl)methyl)-5-(4-bromophenyl)-1-(2-chlorophenyl)-N-(1-phenylcyclopropyl)-1H-pyrazole-3-carboxamide 
• 1191066-44-0 4-{[(4-chlorobenzenesulfonyl)pyridin-2-ylmethylamino]methyl}-N-(1-phenylcyclopropyl)benzamide 
• 1191066-49-5 C₃₀H₂₆N₄O₃S 
• 1259392-35-2 C₃₁H₂₇N₃O₃S 
• 1336960-20-3 3-(1,4'-bipiperidin-1'-ylmethyl)-2-(3-chlorophenyl)-N-(1-phenylcyclopropyl)-4-quinolinecarboxamide trifluoroacetate 
• 1439556-98-5 C₃₇H₃₈N₆O₃S 
• 1422208-41-0 C₂₄H₃₂N₂O₃ 
• 1422207-63-3 C₃₃H₄₁N₃O₃ 
• 1422208-57-8 C₁₉H₂₄N₂O*ClH 
• 1245647-91-9 C₁₃H₁₈N₂ 
• 1384445-09-3 N-(4-(4-(1-phenylcyclopropyl)piperazine-1-carbonyl)phenyl)quinoline-8-sulfonamide 
• 1384448-13-8 C₂₀H₂₄N₂O₂S 

Relevant academic research and scientific papers

METALLOENZYME INHIBITOR COMPOUNDS

Provided are compounds having HDAC6 modulating activity, and methods of treating diseases, disorders or symptoms thereof mediated by HDAC6.

Pyruvate kinase activators for use in therapy

Described herein are methods for using compounds that activate pyruvate kinase.

THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE

Provided are compounds useful for treating cancer and methods of treating cancer comprising administering to a subject in need thereof a compound described herein.

COMBINATIONS OF HISTONE DEACETYLASE INHIBITORS AND EITHER HER2 INHIBITORS OR PI3K INHIBITORS

The invention relates to combinations comprising an HDAC inhibitor and a Her2 inhibitor for the treatrent of breast cancer in a subject in need thereof. The invention also relates to combinations comprising an HDAC inhibitor and a PI3K inhibitor for the treatment of breast cancer in a subject in need thereof. Also provided herein are methods for treating breast cancer in a subject in need thereof comprising administering to the subject an effective amount of one of the above combinations. Further provided are methods for inhibiting migration and/or invasion of a breast cancer cell in a subject by administering to the subject a HDAC6 specific inhibitor.

HDAC INHIBITORS, ALONE OR IN COMBINATION WITH BTK INHIBITORS, FOR TREATING NONHODGKIN'S LYMPHOMA

The invention relates to HDAC inhibitors, or combinations comprising an HDAC inhibitor and a BTK inhibitor for the treatment of non-hodgkin's lymphoma in a subject in need thereof. Also provided herein are methods for treating non-hodgkin's lymphoma in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an HDAC inhibitor, or a combination comprising an HDAC inhibitor and a BTK inhibitor.

HDAC Inhibitors, Alone Or In Combination With PI3K Inhibitors, For Treating Non-Hodgkin's Lymphoma

The invention relates to HDAC inhibitors, or combinations comprising an HDAC inhibitor and a PI3K inhibitor for the treatment of non-hodgkin's lymphoma in a subject in need thereof. Also provided herein are methods for treating non-hodgkin's lymphoma in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an HDAC inhibitor, or a combination comprising an HDAC inhibitor and a PI3K inhibitor.

PIPERAZINE AND HOMOPIPERAZINE DERIVATIVES AS HIV ATTACHMENT INHIBITORS

Compounds of Formula I, including pharmaceutically acceptable salts thereof, are useful as HIV attachment inhibitors.

THERAPEUTIC COMPOUNDS AND COMPOSITIONS

Compounds and compositions comprising compounds that modulate pyruvate kinase M2 (PKM2) are described herein. Also described herein are methods of using the compounds that modulate PKM2 in the treatment of cancer.

NICOTINAMIDES AS JAK KINASE MODULATORS

The present invention is directed to compounds of formula I and pharmaceutically acceptable salts, esters, and prodrugs thereof which are inhibitors of JAK kinase. The present invention is also directed to intermediates used in making such compounds, the preparation of such a compound, pharmaceutical compositions containing such a compound, methods of inhibition JAK kinase activity, methods of inhibition the platelet aggregation, and methods to prevent or treat a number of conditions mediated at least in part by JAK kinase activity, such as undesired thrombosis and Non Hodgkin's Lymphoma.

INHIBITORS OF JAK

The present invention is directed to compounds of formula (I) and tautomers and pharmaceutically acceptable salts thereof which are selective inhibitors of JAK. The present invention is also directed to intermediates used in making such compounds, the preparation of such a compound, pharmaceutical compositions containing such a compound, methods of inhibition JAK activity, and methods to prevent or treat a number of conditions mediated at least in part by JAK activity.